Dramatic Prostate Specific Antigen Decrease in Response to Discontinuation of Megestrol Acetate in Advanced Prostate Cancer: Expansion of the Antiandrogen Withdrawal Syndrome-Reference-Cited by-同舟云学术

Dramatic Prostate Specific Antigen Decrease in Response to Discontinuation of Megestrol Acetate in Advanced Prostate Cancer: Expansion of the Antiandrogen Withdrawal Syndrome

Published:1995-06 Issue:6 Volume:153 Page:1946-1947
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Dawson Nancy A.¹,McLeod David G.¹

Affiliation:

1. Hematology-Oncology and Urology Services, Walter Reed Army Medical Center, Washington, D. C

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference11 articles.

1. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer;Scher;J. Clin. Oncol.,1993

2. Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy;Dupont;J. Urol.,1993

3. Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of “hormone-refractory” prostate cancer;Sartor;J. Natl. Cancer Inst.,1994

4. Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer;Figg;Amer. J. Med.,1995

5. Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation;Veldscholte;Biochemistry,1992

Cited by 105 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comprehensive Analysis of AR Alterations in Circulating Tumor DNA from Patients with Advanced Prostate Cancer;The Oncologist;2019-11-11

2. Delayed Antiandrogen Withdrawal Syndrome After Discontinuation of Bicalutamide;Clinical Genitourinary Cancer;2015-02

3. Switching and withdrawing hormonal agents for castration-resistant prostate cancer;Nature Reviews Urology;2015-01

4. Is there an antiandrogen withdrawal syndrome with enzalutamide?;BJU International;2014-10-24

5. Identification of a new androgen receptor (AR) co-regulator BUD31 and related peptides to suppress wild-type and mutated AR-mediated prostate cancer growth via peptide screening and X-ray structure analysis;Molecular Oncology;2014-06-24